Proteomic analysis of glioblastomas: what is the best brain control sample?

Jean-Michel Lemée; Emmanuelle Com; Anne Clavreul; Tony Avril; Véronique Quillien; Marie De Tayrac; Charles Pineau; Philippe Menei

doi:10.1016/j.jprot.2013.04.031

Proteomic analysis of glioblastomas: what is the best brain control sample?

Jean-Michel Lemée ^{1, 2, *} Emmanuelle Com ³ Anne Clavreul ^{1, 2} Tony Avril ⁴ Véronique Quillien ⁴ Marie De Tayrac ^{4, 5} Charles Pineau ³ Philippe Menei ^{1, 2}

* Auteur correspondant

1 Service de neurochirurgie

2 MINT - Micro et nanomédecines biomimétiques

3 Plateforme Protéomique-Biogenouest (PPB)

Irset - Institut de recherche, santé, environnement et travail, Protim - Proteomics Core Facility

4 IGDR - Institut de Génétique et Développement de Rennes

5 Service de Génétique Moléculaire et Génomique

Abstract : UNLABELLED: Glioblastoma (GB) is the most frequent and aggressive tumor of the central nervous system. There is currently growing interest in proteomic studies of GB, particularly with the aim of identifying new prognostic or therapeutic response markers. However, comparisons between different proteomic analyses of GB have revealed few common differentiated proteins. The types of control samples used to identify such proteins may in part explain the different results obtained. We therefore tried to determine which control samples would be most suitable for GB proteomic studies. We used an isotope-coded protein labeling (ICPL) method followed by mass spectrometry to reveal and compare the protein patterns of two commonly used types of control sample: GB peritumoral brain zone samples (PBZ) from six patients and epilepsy surgery brain samples (EB) pooled from three patients. The data obtained were processed using AMEN software for network analysis. We identified 197 non-redundant proteins and 35 of them were differentially expressed. Among these 35 differentially expressed proteins, six were over-expressed in PBZ and 29 in EB, showing different proteomic patterns between the two samples. Surprisingly, EB appeared to display a tumoral-like expression pattern in comparison to PBZ. In our opinion, PBZ may be more appropriate control sample for GB proteomic analysis. BIOLOGICAL SIGNIFICANCE: This manuscript describes an original study in which we used an isotope-coded protein labeling method followed by mass spectrometry to identify and compare the protein patterns in two types of sample commonly used as control for glioblastoma (GB) proteomic analysis: peritumoral brain zone and brain samples obtained during surgery for epilepsy. The choice of control samples is critical for identifying new prognostic and/or diagnostic markers in GB.

keyword : Proteomic Glioblastoma ICPL Epilepsy

Type de document :

Article dans une revue

Journal of Proteomics, Elsevier, 2013, 85, pp.165-73. 〈10.1016/j.jprot.2013.04.031〉

Domaine :

Sciences du Vivant [q-bio] / Génétique

Liste complète des métadonnées

Littérature citée [34 références] Voir Masquer Télécharger

http://www.hal.inserm.fr/inserm-00871494
Contributeur : Laurent Jonchère <>
Soumis le : mercredi 9 octobre 2013 - 16:25:07
Dernière modification le : mercredi 18 juillet 2018 - 20:02:03
Document(s) archivé(s) le : vendredi 10 janvier 2014 - 04:24:48

ManuscritProt-accepted.pdf

Fichiers produits par l'(les) auteur(s)

Proteomic analysis of glioblastomas: what is the best brain control sample?

Fichiers

Identifiants

Collections

Citation

Exporter

Métriques

616

891

Contact

Proteomic analysis of glioblastomas: what is the best brain control sample?

Fichiers

Identifiants

Collections

Citation

Exporter

Partager

Métriques

616

891

Contact